A Review on Reconciliation of Natural Product Bioactivity, Pharmacokinetic Roadblocks, and Ethnopharmacogenomics in Oncology

Review Article

Abstract

Cancer disparities in low- and middle-income countries remain severe due to the prohibitive costs and infrastructural requirements of next-generation sequencing and targeted molecular biologics. While traditional botanical medicine offers a vast, structurally different reservoir of bioactive secondary metabolites, translating these traditional resources into clinically validated oncological interventions requires a rigorous scientific study. This review presents the conceptual and practical integration of ethnopharmacological knowledge with tumor genomic profiling and host pharmacogenomics. In vitro studies show that major classes of plant-derived compounds, including alkaloids, polyphenols, terpenoids, and organosulfur molecules, modulate key oncogenic cascades such as the PI3K/AKT/mTOR, MAPK/ERK, and NF-κB pathways. However, the clinical translation of these benefits is severely constrained by profound pharmacokinetic barriers. Rather than host genetic variation in drug-metabolizing enzymes, the primary impediments to clinical efficacy for prominent compounds like curcumin and withaferin A are extremely low aqueous solubility, rapid Phase-II glucuronidation, chemical instability, and prominent Pan-Assay Interference Compounds characteristics. Reconciling these physical and metabolic limitations requires an objective evaluation of herb-drug interactions, standardized phytochemical profiling, and the implementation of host-tumor genomic stratification. Researchers can systematically categorize compound-target interactions and prioritize candidates for rigorous validation by utilizing computational approaches such as structural molecular docking, network pharmacology, and machine learning. Cultivating an ethically sound, epistemologically just translational pipeline in resource-limited settings necessitates clear regulatory guidelines, standardized quality controls, and equitable benefit-sharing arrangements that protect indigenous intellectual property